Back

396 Views

Clinical Practice (assessment, diagnosis, treatment, knowledge translation/EBP, implementation science, program development)

Switching Adults With Spasticity From OnabotulinumtoxinA to AbobotulinumtoxinA: Real-World Data Across Three US-Based Centers

Thursday, November 10, 2022

4:04 PM – 4:09 PM

Location: Station 4

Non-presenting Author(s)

NW

Nate Way, PhD

Senior Evidence Generation RWE Lead
Real World Evidence, Cerner Enviza
North Kansas City, Missouri, United States
ED

Edward Dabrowski, MD

Director
Beaumont Health
Grosse Point, Michigan, United States
MP

Mitchell Paulin, MD

Director
The Center for Tone Management
Paoli, Pennsylvania, United States
MT

Martin Taylor, DO, PhD

Neurologist
OrthoNeuro
New Albany, Ohio, United States
JM

John Madden, PhD

Medical Science Liaison, Neuroscience
Ipsen Pharmaceuticals
Cambridge, Massachusetts, United States
AM

Amandeep Mann, PhD, MS

Director of Medical Affairs
Ipsen Pharmaceuticals
Cambridge, Massachusetts, United States

Presenting Author(s)

JB

Jonathan Bouchard, MS, RPh

Director of HEOR
Ipsen Pharmaceuticals
Cambridge, Massachusetts, United States

Research Objectives: To illustrate the safe transitioning from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A) in adults with spasticity.

Design: Retrospective study of patient chart data.

Setting: Three US-based treatment centers.

Participants: Patients aged ≥18 years with upper limb (ULS), lower limb (LLS), or ULS and LLS (ULS+LLS) spasticity.

Interventions: ≥2 onaBoNT-A treatment cycles, followed by ≥3 aboBoNT-A treatment cycles.

Main Outcome Measures: The transition of patients from onaBoNT-A to aboBoNT-A.

Results: A total of 88 patients (mean±SD age 44.9±19.6; 62.5% male) switched from onaBoNT-A to aboBoNT-A; in 84 (95.5%), the switch was due to “medical need/effectiveness not achieved.” Spasticity etiologies included stroke (25.0%), traumatic brain injury (13.6%), spinal cord injury (2.3%), cerebral palsy (42.0%), multiple sclerosis (9.1%), and other (8.0%). Fifty-one patients (58.0%) had bilateral spasticity, with 5.0±2.2 muscles injected at each visit over the 5-injection-cycle treatment period. Across the 2 initial cycles prior to the switch, mean doses of onaBoNT-A were 425.0±179.0U, 477.1±132.8U, and 454.2±156.0U for ULS, LLS, and ULS+LLS, respectively; following the switch, mean aboBoNT-A doses across 3 treatment cycles were 1005.1±439.2U, 1006.2±334.2U, and 1203.2±325.7U, respectively. No adverse events (AEs) were reported following conversion.

Conclusions: Patients who switched from onaBoNT-A to aboBoNT-A continued for at least 3 treatment cycles without any reported AEs. Mean doses of both onaBoNT-A and aboBoNT-A were generally aligned with the upper ranges of their respective dosing guidelines. Further randomized crossover studies evaluating the efficacy and safety of onaBoNT-A versus aboBoNT-A are warranted.

Author(s) Disclosures: NW: Employee of Cerner Enviza (Kantar Health); ED: Received consultancy fees and/or research support from Allergan, Ipsen, Solstice, Merz; MP and MT: None; JM, AM, and JB: Employees of Ipsen.

Learning Objectives:

Upon completion, participant will be able to understand the ability to safely transition patients from onaBoNT-A to aboBoNT-A therapy.
Upon completion, participant will be able to recognize the significance of further evaluating the efficacy and safety of onaBoNT-A vs aboBoNT-A in randomized controlled studies.
Upon completion, participant will be able to have a broader understanding of physicians’ use of toxin therapy to manage various types of limb spasticity in real-world, clinical practice.
Upon completion, participant will be able to appreciate the importance of evidence-based practice to inform clinical decision making for treatment and management of spasticity.